Information Registration Programme Overview Satellite Education Programme Virtual Exhibitor Listing


All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Search Abstracts by author or title


Treatment of cornea-conjunctival intraepithelial neoplasia (CIN) with IFN alfa-2B in Galdakao Hospital: a 5-year retrospective study

Poster Details

First Author: I. Gutiérrez Santamaría SPAIN

Co Author(s):    J. Alberdi Alberdi   C. López Gutiérrez   E. Corcóstegui Cortina   X. Lertxundi Plaza   A. Urkia Solorzano   M. Graña Lecuona     

Abstract Details


Study the tolerance, effectiveness, mean treatment time and associated carcinomas of IFN alpha-B2 in patients with a clinical diagnosis of CIN.


Hospital de Galdakao, Biscay, Spain.


All patients treated with IFN alpha-2B between the dates of January 1, 2014 and October 9, 2019 were searched. Among them, those with a clinical diagnosis of CIN were included. Two groups were established, those treated as the first line with IFN alfa-2B and those in which it was used as an adjunct to surgery.


The mean age of the included patients was 73 years. 82% were men. Tolerance of INF alpha-2B treatment was good in 82% of cases. In one case, conjunctival hyperemia was presented that did not end the treatment. The mean duration of treatment was 3.7 months, the mode being 3 months. The main result was 0% relapses in those treated with IFN alfa-2B in both groups. In 73% of the patients, an associated systemic carcinoma was found, mainly in the ENT area. Treatment with INF alpha - 2B was effective for the treatment of CIN in our group of patients.


IFN alpha-2B has shown good tolerance in 82% of patients with CIN. In this group of patients, the recurrence rate in CIN treated with IFN alfa-2B was 0%. The mean duration of IFN alpha-2B treatment in this group of patients was 3-4 months. 73% of the patients with CIN had associated systemic carcinomas. A complete history is recommended to diagnose other coexisting systemic carcinomas.

Financial Disclosure:


Back to Poster listing